Improving the Evaluation and Management of Transfusion‐Related Iron Overload in Children, Adolescents, and Young Adults Following Cancer Treatment or Hematopoietic Stem Cell Transplantation
Pediatric Blood & Cancer · 2026-06 · 73 (6)
DOI: 10.1002/1545-5017.70275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 31.03.2026. Verfasst von Luke Gingell und 3 weiteren Autor:innen. Beteiligte Einrichtung: Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA. Hauptthemen laut MEDLINE: Iron Overload, Hematopoietic Stem Cell Transplantation, Neoplasms, Erythrocyte Transfusion. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Corewell Health Helen DeVos Children's Hospital Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Transfusion‐related iron overload (TRIO) is a late effect of therapy impacting survivors of childhood cancer and hematopoietic stem cell transplantation (HSCT) who receive frequent packed red blood cell (pRBC) transfusions. Surprisingly, there are no accepted guidelines to assist providers in identifying and treating at‐risk patients. Our primary aim was to create a clinical practice guideline (CPG) for the surveillance of TRIO and measure its impact on care at Helen DeVos Children's Hospital. Procedure We compared the rates at which screening laboratory and confirmatory imaging studies were obtained 2 years before and 6 months after CPG implementation. We additionally sought to characterize the patients at our institution who developed TRIO.
Results
Labs more commonly obtained post‐implementation included iron studies such as TIBC ( p = 0.0077), TSAT ( p = 0.0133), and serum iron ( p = 0.0208), and hepatic injury markers such as AST/ALT ( p = 0.0278), ALP ( p = 0.0073), and total bilirubin ( p = 0.0026). Liver MRI/FerriScan ( p = 0.0343) and echocardiogram were also more commonly obtained post‐implementation. We additionally found a positive correlation between the number of pRBC transfusions and TRIO ( p = 0.0025). Gender, age, and weight did not impact the rates of TRIO in either cohort. There was no association between diagnosis category (solid tumor, leukemia/lymphoma, or nonmalignant disease) and TRIO. All patients who developed TRIO received a minimum of 12 months of therapy.
Conclusions
The implementation of a TRIO CPG can significantly influence TRIO screening practices, likely expediting treatment and potentially reducing post‐therapy complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.
- Section of Pediatric Hematology/Oncology, Corewell Health Helen Devos Children's Hospital, Grand Rapids, Michigan, USA.
- Michigan State University Center for Statistical Training & Consulting (CSTAT), East Lansing, Michigan, USA.
- Section of Pediatric Bone Marrow Transplantation and Cellular Therapy, Corewell Health Helen Devos Children's Hospital, Grand Rapids, Michigan, USA.
ORCID-Profile: Luke Gingell, Allison Close, Troy C Quigg
Förderung
- Corewell Health Helen DeVos Children's Hospital Foundation
Zitieren
APA
Gingell, L., Close, A., Zhou, G., & Quigg, T. C. (2026). Improving the Evaluation and Management of Transfusion‐Related Iron Overload in Children, Adolescents, and Young Adults Following Cancer Treatment or Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer, 73(6). https://doi.org/10.1002/1545-5017.70275
Vancouver
Gingell L, Close A, Zhou G, Quigg TC. Improving the Evaluation and Management of Transfusion‐Related Iron Overload in Children, Adolescents, and Young Adults Following Cancer Treatment or Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer. 2026;73(6). doi:10.1002/1545-5017.70275
BibTeX
@article{Gingell2026,
author = {Gingell, Luke and Close, Allison and Zhou, Guoli and Quigg, Troy C},
title = {Improving the Evaluation and Management of Transfusion‐Related Iron Overload in Children, Adolescents, and Young Adults Following Cancer Treatment or Hematopoietic Stem Cell Transplantation},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {6},
doi = {10.1002/1545-5017.70275}
}
EUVIMED